Repligen appoints Martin D. Madaus to board; board expands to 8

REPLIGEN CORP

Martin Madaus, Ph.D., joined Repligen's board effective Feb 6, 2023, also named to Nominating and Corporate Governance Committee.
Board size increased from seven to eight directors upon Madaus' election.
Madaus received initial option grant valued at $170,000, vesting equally over three years.
Pro-rata equity award of options and RSUs each valued at $21,250, vesting at next annual shareholder meeting.
Madaus brings over 25 years of life sciences tools industry experience, including CEO roles at Millipore and Ortho Clinical Diagnostics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin Madaus

Director

RGEN · REPLIGEN CORP

Effective: 2023-02-06
Filed: February 9, 2023, 6:59 PM ET

the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Madaus was elected as Director at REPLIGEN CORP.

Action: elected
Role: Director

Exact text from the filing

the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023

View on SEC.gov

REPLIGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-23-029218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.